Expression data from mobilized human CD34+ cells
Ontology highlight
ABSTRACT: Bortezomib-based secondary induction therapy and mobilization could represent alternative strategies to reduce tumor burden. We used microarrays to investigate genome-wide expression changes between bortezomib and non-bortzomib mobilizaton strategies and identified distinct genes and pathways that were significantly differentially regulated. CD34+ stem cells were enriched from leukapheresis products from multiple myeloma patients treated with a bortezomib- or non-bortezomib-based mobilization. RNA extraction, amplification and hybridization on Affymetrix microarrays was performed. Post-induction stem cell collection was initiated when patients' ANC reached >1.0M-CM-^W10^9/L.
ORGANISM(S): Homo sapiens
SUBMITTER: Maureen Lane
PROVIDER: E-GEOD-43124 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA